TARRYTOWN, N.Y. and PARIS, March 10, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
TARRYTOWN, Regeneron Pharmaceuticals, Inc. Sanofi today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the ...
- Praluent will be available in both a 75 mg and 150 mg dose for self-administration every two weeks - Paris and Tarrytown, New York - September 28, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and BRIDGEWATER, N.J, Dec. 11, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that UnitedHealth Group will provide preferred access to Praluent ...
PARIS and TARRYTOWN, N.Y., March 10, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the ODYSSEY OUTCOMES trial met its primary ...
DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Dear Dr. Roach: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results